Related Experiment Video

Updated: Jun 8, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody

Kerstin Fortmüller1, Karen Alt, Dorothee Gierschner

  • 1Department of Urology, Experimental Urology, University Hospital Freiburg, Freiburg, Germany.

The Prostate
|October 15, 2010
PubMed
Abstract

Insights

A novel bispecific diabody redirects T-lymphocytes to target prostate cancer cells expressing prostate specific membrane antigen (PSMA). This immunotherapy approach effectively inhibited tumor growth in preclinical models.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Prostate cancer immunotherapy aims to redirect T-lymphocytes for cancer cell lysis.
  • Prostate specific membrane antigen (PSMA) is a target for prostate cancer therapy.
  • Bispecific single-chain (bsc) diabodies can engage T-cells and tumor antigens.

Purpose of the Study:

  • To construct and evaluate a novel bispecific single-chain (bsc) diabody targeting PSMA and CD3.
  • To assess the binding affinity and cytotoxic potential of the PSMA × CD3 bsc diabody.
  • To determine the in vivo efficacy of the PSMA × CD3 bsc diabody in a prostate cancer xenograft model.

Main Methods:

  • Generation of the PSMA × CD3 bsc diabody from anti-CD3 and anti-PSMA single-chain variable fragments (scFvs).
  • Expression in E. coli and purification using immobilized metal affinity chromatography (IMAC).
  • In vitro assessment of binding, T-cell activation, and cancer cell lysis; in vivo evaluation in a C4-2 xenograft-SCID mouse model.

Main Results:

  • Specific binding of the PSMA × CD3 bsc diabody to CD3-positive Jurkat cells and PSMA-expressing C4-2 cells confirmed by flow cytometry.
  • The diabody demonstrated potent in vitro retargeting of CD4+ and CD8+ lymphocytes to lyse C4-2 prostate cancer cells.
  • In vivo administration of the diabody with human lymphocytes significantly inhibited tumor growth in C4-2 xenograft-bearing SCID mice.

Conclusions:

  • The PSMA × CD3 bsc diabody is a promising therapeutic agent for prostate cancer immunotherapy.
  • This bispecific diabody effectively redirects T-cells to eliminate PSMA-expressing prostate cancer cells.
  • Preclinical data support the potential of this novel immunotherapy for prostate cancer treatment.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.